F Rosignolo1, V Maggisano2, M Sponziello1, M Celano2, C R T Di Gioia3, M D'Agostino2, L Giacomelli4, A Verrienti1, M Dima1, V Pecce1, C Durante5. 1. Department of Internal Medicine and Medical Specialties, University of Rome "Sapienza", Viale del Policlinico155, 00161, Rome, Italy. 2. Department of Health Sciences, University of Catanzaro 'Magna Graecia', 88100, Catanzaro, Italy. 3. Department of Radiological, Oncological and Pathological Sciences, University of Rome "Sapienza", 00161, Rome, Italy. 4. Department of Surgical Sciences, University of Rome "Sapienza", 00161, Rome, Italy. 5. Department of Internal Medicine and Medical Specialties, University of Rome "Sapienza", Viale del Policlinico155, 00161, Rome, Italy. cosimo.durante@uniroma1.it.
Abstract
PURPOSE: Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several human malignancies, including thyroid cancer. In this study, we analyzed THRβ mRNA expression in surgical specimens from a series of human papillary thyroid carcinomas (PTCs), characterized by their genotypic and clinical-biological features. METHODS: Thirty-six PTCs were divided into two groups according to the 2009 American Thyroid Association risk classification (17 low, 19 intermediate), and each group was divided into subgroups based on the presence or absence of the BRAFV600E mutation (21 BRAF mutated, 15 BRAF wild type). Gene expression was analyzed using fluidic cards containing probes and primers specific for the THRβ gene, as well as for genes of thyroperoxidase (TPO), sodium/iodide symporter (NIS), thyroglobulin (Tg) and thyroid stimulating hormone receptor (TSH-R) and for some miRNAs involved in thyroid neoplasia and targeting THRβ. The mRNA levels of each tumor tissue were compared with their correspondent normal counterpart. RESULTS: THRβ transcript was down-regulated in all PTCs examined. No significant differences were found between intermediate- vs low-risk PTCs patients, and BRAF-mutated vs BRAF wild-type groups. THRβ expression was directly correlated with NIS, TPO, Tg and TSH-R, and inversely correlated to miR-21, -146a, -181a and -221 expression. CONCLUSIONS: Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
PURPOSE: Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several humanmalignancies, including thyroid cancer. In this study, we analyzed THRβ mRNA expression in surgical specimens from a series of humanpapillary thyroid carcinomas (PTCs), characterized by their genotypic and clinical-biological features. METHODS: Thirty-six PTCs were divided into two groups according to the 2009 American Thyroid Association risk classification (17 low, 19 intermediate), and each group was divided into subgroups based on the presence or absence of the BRAFV600E mutation (21 BRAF mutated, 15 BRAF wild type). Gene expression was analyzed using fluidic cards containing probes and primers specific for the THRβ gene, as well as for genes of thyroperoxidase (TPO), sodium/iodide symporter (NIS), thyroglobulin (Tg) and thyroid stimulating hormone receptor (TSH-R) and for some miRNAs involved in thyroid neoplasia and targeting THRβ. The mRNA levels of each tumor tissue were compared with their correspondent normal counterpart. RESULTS: THRβ transcript was down-regulated in all PTCs examined. No significant differences were found between intermediate- vs low-risk PTCs patients, and BRAF-mutated vs BRAF wild-type groups. THRβ expression was directly correlated with NIS, TPO, Tg and TSH-R, and inversely correlated to miR-21, -146a, -181a and -221 expression. CONCLUSIONS: Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub Journal: Nature Date: 2005-06-09 Impact factor: 49.962
Authors: Olaia Martínez-Iglesias; Susana Garcia-Silva; Stephan P Tenbaum; Javier Regadera; Fernando Larcher; Jesus M Paramio; Bjorn Vennström; Ana Aranda Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: A L Galrão; A K Sodré; R Y Camargo; C U Friguglietti; M A Kulcsar; E U Lima; G Medeiros-Neto; I G S Rubio Journal: Endocrine Date: 2012-09-01 Impact factor: 3.633